|1.||Nicolaides, K H: 51 articles (09/2015 - 05/2000)|
|2.||Nicolaides, Kypros H: 40 articles (11/2015 - 10/2002)|
|3.||Spencer, K: 39 articles (09/2015 - 02/2000)|
|4.||Conover, Cheryl A: 30 articles (12/2015 - 04/2002)|
|5.||Spencer, Kevin: 25 articles (11/2013 - 10/2002)|
|6.||Oxvig, Claus: 20 articles (12/2015 - 04/2002)|
|7.||Wright, D: 20 articles (07/2015 - 05/2008)|
|8.||Kagan, K O: 18 articles (04/2013 - 09/2007)|
|9.||Bale, Laurie K: 14 articles (10/2015 - 04/2002)|
|10.||Christiansen, Michael: 13 articles (03/2015 - 03/2002)|
|1.||Down Syndrome (Down's Syndrome)
01/01/2006 - "First trimester screening using maternal age, NT, free beta-hCG and PAPP-A is highly effective for the detection of trisomy 21 and is associated with a sensitivity of about 90% for 5% false-positive patients."
06/01/1998 - "This study evaluates diagnostic efficacy of PAPP-A and F beta-hCG in the detection of first trimester pregnancy abnormalities, including Down syndrome (DS). "
04/01/2014 - "in our study population the detection rate for trisomy 21, using the combined risk calculation based on maternal age, fetal NT, maternal PAPP-A and free β-hCG levels, was superior to the application of either parameter alone. "
01/01/2014 - "Previous studies showed that soluble LHCGR/hCG-sLHCGR concentrations in serum or plasma combined with PAPP-A and free βhCG significantly increased the sensitivity of Down's syndrome screen at early pregnancy without altering the false positive rate. "
07/01/2009 - "This study has validated the new risk algorithm and demonstrated that in combined screening for trisomy 21 based on maternal age, fetal NT and free beta-hCG and PAPP-A the detection rate is about 90% for a 3% false-positive rate."
10/01/2005 - "The combination of first trimester serum PAPP-A and uterine artery mean PI at 22-24 weeks improves the screening efficacy for the prediction of pre-eclampsia."
01/01/2014 - "Some studies have demonstrated an even more pronounced decrease of PAPP-A in the early second trimester of pregnancy in women who subsequently develop preeclampsia compared with women who do not develop preeclampsia. "
01/01/2013 - "The aim of this study was to determine the serum values of β-hCG in the first and second trimesters of pregnancy and PAPP-A values in the first trimester of pregnancy in pregnant women with risk factors for preeclampsia, in order to evaluate their relevance in the prediction of this disorder. "
01/01/2013 - "The aim of this study was to analyze the values of concentration of PAPP-A in assessment of progress and outcome of pregnancy in pregnant women diagnosed with threatening preterm delivery, preeclampsia and fetal growth restriction in relation to physiological pregnancy of the same gestational age. "
12/01/2011 - "Our study indicates the association of TT genotype of Cys327Cys polymorphism of the PAPP-A gene with preeclampsia. "
|3.||Acute Coronary Syndrome
01/01/2015 - "In this study 927 patients with CAD (534 with stable angina and 393 with acute coronary syndrome [ACS]) and 217 patients without CAD and measured PAPP-A levels were included. "
03/01/2012 - "Recent studies have reported that elevated levels of PAPP-A, signal the onset of acute coronary syndrome (ACS). "
05/01/2011 - "This study aimed to investigate the relationship between the levels of circulating PAPP-A and the mid-term outcomes of percutaneous coronary intervention (PCI) in patients with non-ST-elevation acute coronary syndrome. "
09/01/2007 - "Previous studies have shown PAPP-A to be a significant marker of plaque instability and cardiovascular events in patients with acute coronary syndromes. "
07/01/2005 - "A special emphasis was placed on those that address the development of methods for the detection of PAPP-A in human serum/plasma and those that study the diagnostic/prognostic accuracy of PAPP-A in patients with acute coronary syndrome. "
04/01/2015 - "Following confirmation of mAb-PA bioavailability and target efficacy in vivo, the antitumor efficacy of mAb-PA in multiple Ovatar tumor models was examined and the response was found to depend on PAPP-A expression. "
10/13/2015 - "In experimental animals, PAPP-A accelerates ovarian tumor growth by this mechanism. "
12/01/2014 - "PAPP-A staining in tumor tissue was detected in 45 of 46 specimens. "
12/01/2014 - "PAPP-A has been implicated in several cancers. "
04/01/2011 - "Investigation of angiogenesis indicated that overexpression of PAPP-A favored development of mature tumor vasculature and that tumor precursors of PAPP-A-28 in particular had a significantly higher degree of vascularization months before obvious tumor development. "
|5.||Chromosome Aberrations (Chromosome Abnormalities)
11/01/2013 - "Recent studies suggest that PAPP-A may be involved in clinical conditions related to unwanted cellular growth, and the circulating levels of PAPP-A is an established biomarker in prenatal screening for chromosomal abnormalities. "
11/01/2009 - "The measurement sensitivity of the fetal nuchal translucency in detection of the fetal chromosomal abnormalities was 80% and sensitivity of serum concentrations of PAPP-A and free beta-HCG was 40% and 80%. "
11/01/2009 - "Estimation the sensitivity of the fetal nuchal translucency measurement, biochemical concentrations of PAPP-A and free beta-HCG in detection of the fetal chromosomal abnormalities. "
06/01/2009 - "In the absence of chromosome abnormality, pregnancy outcomes were defined as 'normal' in at least 30% and 'good' in at least 60%, with both percentages increasing as the PAPP-A level rose. "
02/01/2008 - "Low levels of maternal serum PAPP-A are associated, in the absence of an abnormal karyotype, with an increased risk of preterm or early preterm delivery. "
|1.||Pregnancy-Associated Plasma Protein-A (PAPP-A)
|2.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)
|3.||Biological Markers (Surrogate Marker)
|6.||Insulin-Like Growth Factor I (IGF-1)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Pregnancy-Specific beta 1-Glycoproteins
|9.||Tissue Inhibitor of Metalloproteinases (TIMP)
|10.||Messenger RNA (mRNA)
|2.||Cesarean Section (Caesarean Section)
|4.||Transplantation (Transplant Recipients)
|5.||Renal Dialysis (Hemodialysis)